EU green light for Zogenix’s Fintepla
Oral solution approved to treat seizures associated with Dravet syndrome
Read More
Tag: Dravet syndrome
UK Home Office loosens restrictions on GW’s Epidyolex
The cannabinoid has been reclassified as a Schedule 5 medicine meaning that it can be dispensed more easily
Read More
GW Pharma’s Epidiolex nears US launch
GW Pharmaceuticals and its subsidiary Greenwich Biosciences are gearing up to launch Epidiolex in the US after drug enforcement officials re-classified the cannabis-based medicine to the lowest restriction.
Read More
US clears new treatment option for Dravet syndrome
US regulators have approved Biocodex’ Diacomit for the treatment of seizures associated with Dravet syndrome (DS), a rare and difficult to treat form of epilepsy.
Read More
Zogenix’ drug cuts seizures in Dravet syndrome
Zogenix has revealed top-line results from a second late-stage trial of its investigational Dravet syndrome drug ZX008, showing a significant reduction in seizures.
Read More
FDA approves GW’s cannabinoid drug Epidiolex
GW Pharmaceuticals’ Epidiolex has become the first cannabinoid prescription medicine to be approved in the US, winning clearance to treat two rare forms of epilepsy.
Read More
FDA advisors back approval of GW’s Epidiolex
As expected, an FDA advisory panel has backed approval of GW Pharmaceuticals/Greenwich Bioscience’s Epidiolex for treating seizures associated with Lennox-Gastaut syndrome and Dravet syndrome.
Read More
GW completes Epidiolex submission
GW Pharmaceuticals and its US subsidiary Greenwich Biosciences have completed the rolling submission of Epidiolex as adjunctive treatment of seizures associated with Lennox-Gastaut syndrome and Dravet syndrome, two difficult-to-treat forms of childhood-onset epilepsy.
Read More
GW Pharma poised to file Epidiolex in the US
GW Pharmaceuticals is on the brink of filing its cannabis-derived therapy Epidiolex in the US as another late-stage study highlights the drug’s efficacy in treating Dravet Syndrome, a rare and severe type of epilepsy.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
